Rome, 30 Jun. (AdnKronos Salute) – The approval of the refunding by the National Health System of Secukinumab, a recombinant single -selective single -human antibodor for the interleuchin -17a -19th, in the treatment of suppurative hydrosadenitis (inverse acne), active in severi in adults with an inadequate response to the conventional systemic therapy for HS, was published in the Official Gazette. complex disease and many psychological implications. Novartis announces it in a note. The safety and effectiveness of the drug have been evaluated in 2 phase III studies – Sunshine and Sunrise -Randomized, in double blind and controlled with placebo, conducted on adult patients suffering from supplementary hydrosadenitis (HS) from moderate to Severo and candidates for systemic biological therapy. Studies have shown that the treated patients have obtained a significant response in the decrease in the number of inflammatory abscesses and nodules and have expressed a clinically relevant decrease in skin pain linked to the pathology.
“The suppurative hydrosadenitis – explains Angelo Valerio Marzano, director SC Dermatology, IRCCS CA ‘Granda Hospital Maggiore Polyclinic in Milan – is a chronic inflammatory skin disease that manifests itself with nodules, abscesses and fistulas typically at the axillary and inguinal level, while in some cases, extending to the anogenital area and, in general, to the areas of the skin folds. It is typically an early debut, after puberty, and for its complexity, it is estimated, that the delay in the diagnosis is on average between 7 and 10 years.
Advination hydrosadenitis is a complex disease that affects about 1% of the Italian population, in 70% of cases women – informs the pharmaceutical – the debut can also take place in early age, around the age of 18, bringing with it a heavy psychological load. The quality of life of patients is significantly compromised, with a very high impact on personal, social and working life for 48% of patients. The personal sphere, relationships, moods and social life, followed by the work sphere, which for some (30%) was the cause of the loss of work are affected. The strong impact of the pathology, in addition to touching the most intimate and personal sphere, is also dictated by a series of debilitating symptoms: 66% accuses pain, fatigue and itching. For its complexity, the HS requires a multidisciplinary approach – which includes nutritionists, nurses, psychologists, pain therapists and surgeons – and concrete support for the patient, also for surgical interventions that are sometimes necessary, due to over -infections.
“The disease has chronic evolution with periodic, recurrent episodes, with a difficult predictable trend – clarifies Cristina Magnoni, SSD of dermatological surgery with an oncological and regenerative address, Aou Modena – The surgical treatment varies from procedural treatments (laser) and minor interventions (engraving, drainage and Deroofing) up to major surgical interventions (large local excision). Similarly to the approach to the approach. gradual of medical treatments – he continues – surgery is intensified with the increase in the severity of the disease and the presence of irreversible tissue damage, such as tunnels and scars.
There are still too many dissatisfied needs of patients: delays in diagnosis, difficulty in taking charge and weight of stigma and isolation. It is therefore crucial to sensitize public opinion to break down barriers and guarantee a more in -depth training for the medical class, called to manage a pathology still little known. “Novartis aims to improve outcomes for patients and the lives of people with painful and debilitating immunological conditions, such as suppurative hydrosadenitis – says Paola Coco, Chief Scientific Officer & Medical Affairs Head, Novartis Italia – Our commitment takes the form of discovering and making innovative drugs available for complex and little studied immunological pathologies, which present significant, which present significant. dissatisfied therapeutic needs.
In this context, the vision-vite project of suppurative hydrosadenitis in Italy, carried out by Istud Health and Health, in collaboration with the Passion People APS association and promoted by Novartis, to give people with people with HS. By integrating a narrative medicine approach, the project conducted a listening activity at 9 care centers in Italy, collecting 81 testimonies between patients, caregivers and health professionals in a book downloadable for free. Visits explores the experience of patients, deepening the clinical aspects of the disease, but also the personal, emotional, social and cultural dimension. The research – concludes a note – analyzes the impact of the pathology on daily life, on interpersonal relationships and on the workplace, also highlighting the support role of family members and involving dermatologists to understand their therapeutic approach, the challenges and communication strategies adopted to meet the needs of patients.
